Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: 2 sponsored US clinical trials, 2 recruiting.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. The most-studied condition in this pipeline is Lung Cancer, Non-Small Cell, with 1 trials.
Mid-pack sponsor footprint
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Therapeutic Areas
What is open in the Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline
2 recruiting of 2 indexed (100% open).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Lung Cancer, Non-Small Cell (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: open-pipeline peers nationwide
Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Fondazione IRCCS Istituto Nazionale dei Tumori, Milano page
2 registered trials is a research-attention snapshot, not an endorsement of Fondazione IRCCS Istituto Nazionale dei Tumori, Milano or any single study.
- 2 of Fondazione IRCCS Istituto Nazionale dei Tumori, Milano's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer, Non-Small Cell is the condition Fondazione IRCCS Istituto Nazionale dei Tumori, Milano studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer, Non-Small Cell trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline card: 2 registered trials from official public datasets.Report a data error.